 Derivatives of 2,3,4,5,6,7-hexahydro-2,7-methano-1,5-benzoxazonines and -1,4-benzoxazonines, processes for their production and their use as pharmaceuticals |
| We claim: 1. 2,3,4,5,6,7-Hexahydro-2,7-methano-1,5-benzoxazonine and -1,4-benzoxazonine compounds, ... |
|
| Novel benzylalcohol derivatives and processes for preparing the same |
| What we claim is: 1. A compound of the formula: ##STR11## wherein R is a lower alkyl group having 1-... |
|
| Method of use of bicycloheptane substituted prostaglandin analogs as cardiovascular agents |
| What is claimed is: 1. A method of inhibiting arachidonic acid-induced platelet aggregation and ... |
|
| Dihydropyridine derivatives and pharmaceutical composition thereof |
| OF THE INVENTION This invention relates to dihydropyridine derivatives represented by the formula (... |
|
| Use of fedotozine in the treatment of functional states of intestinal obstructions |
| We claim: 1. Process for inhibiting functional ileus in a patient, which consists of administering ... |
|
| Manufacture of pharmaceutical dosage forms |
| OF THE INVENTION The present invention is directed to solid, unit dosage forms primarily for oral ... |
|
| Device comprising liner for protecting fluid sensitive medicament |
| OF THE DRAWING FIGURES Turning now to the drawings in detail, which are examples of various ... |
|
| In situ active compound assembly |
| I claim: 1. A method to modify a target condition contained within an environment with a conjugate ... |
|
|
Sustained release formulations
| Details |
Inventors: Phillips, Reginald; Bikkina, Krishnayya; Khan, Sadath U.;
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Primary Examiner: Lusignan; Michael
Assistant Examiner:
Attorney, Agent or Firm: Olevsky; Howard, Daignault; Ronald A.
Drug delivery systems which exhibit sustained release properties when administered are produced using a "dual control" system which employs polymeric agents in core and membrane portions. |
|
DETAILED DESCRIPTION We claim: 1.
In combination, a drug suitable for oral delivery and a delivery system for sustained release dosage of said drug comprising: (a) a core portion containing about 70 to 90% by weight of the drug and an effective amount of a cellulosic gelling polymer; and (b) a semipermeable membrane around said core containing effective amounts of a water soluble cellulosic polymer and a water insoluble acrylic polymer; said combination having 65 to 80% by weight drug and 20 to 30% by weight of the combination of gelling and membranal polymeric binders of the combination.
2.
The delivery system of claim 1 whenever the core contains hydroxyethyl cellulose.
3.
The delivery system of claim 2 wherein the drug is procainamide hydrochloride.
4.
A process for producing solid dosage forms which exhibit sustained release properties when administered which comprises the steps of: (1) producing a solid core containing effective amounts of at least one drug and at least one cellulosic gelling polymer, and (2) coating the core of step (1) with at least one semipermeable coating which contains effective amounts of water soluble cellulosic and water insoluble acrylic polymer components.
5.
The process of claim 4 wherein the gelling polymer comprises hydroxy ethyl cellulose.
6.
The process of claim 4 wherein there is added the steps of: (3) coating the product of step (2) with a polymeric color coat, and (4) coating the product of step (3) with a polymeric clear coat.
7.
The process of claim 6 wherein the gelling polymer comprises hydroxyethyl cellulose.
Description:
BACKGROUND The self-administration of oral dosage forms is fought with many non-compliance problems.
While some patients do not like the taste or mouthfeel of certain dosage forms, others simply forget to take drugs or other orally-administered beneficial substances.
This invention deals with a dosage form which need be taken no more than twice in a twenty-four hour period.
Optimally it need be administered only once a day
|
| Related patents |
|
|
Water dispersible gemfibrozil compositions
What is claimed is: 1. A water-dispersible formulation of gemfibrozil comprising finely divided particles of pure gemfibrozil uniformly coated with a mixture of a wax ...
|
|
|
Method and composition for enhancing the effect of indirect-acting sympathomimetic amines
OF SPECIFIC EMBODIMENTS In accordance with this invention, tyrosine or a tyrosine precursor such as phenylalanine is administered concomitnatly with an indirect-acting ...
|
|
|
1-azabicycloalkane derivatives, their preparation process and their use as medicaments
What is claimed is: 1. A compound of formula (I) ##STR5## in which n represents the number 1, R.sub.1 and R.sub.2, identical or different represent hydrogen or an ...
|
|
|
Use of specific N-methyl-D-aspartate receptor antagonists in the prevention and treatment of neurodegeneration
OF THE INVENTION The novel method of treatment of neurodegeneration of this invention comprises the administration to a patient in need of such treatment with an ...
|
|
|
Iron citrate complex, process for its production, and its pharmaceutical
We claim: 1. An iron citrate micellar complex, which is a brown solid having the properties set out below: (a) average composition by weight of about: 10.6% carbon, 2.62%...
|
|
|
Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same
OF INVENTION The 4,5-bis(4-methoxyphenyl)-2-(pyrrol-2-yl)thiazoles of the present invention have the formula (I) as described hereinbefore. In the formula (I), the ...
|
|
|
Specifically .beta.-.beta. cross-linked hemoglobins and method of preparation
The present invention provides a modified hemoglobin comprising hemoglobin which is cross-linked with a cross-linking reagent, said cross-linking reagent being selected ...
|
|
|
Apparatus for manufacturing granulated material
The invention proceeds from the consideration that it is not possible to reduce the width of the slit, especially at high production rates i.e., at high relative ...
|
|
|
Substituted and bridged pyridines useful as calcium channel blockers
OF THE INVENTION The specific substituted and bridged pyridine compounds of this invention are represented by the following general structural formula (I): ##STR1## ...
|
|
|
Ace inhibitors in macular degeneration
OF THE INVENTION The novel method of treatment of senile macular degeneration of this invention comprises the administration to a patient in need of such treatment of ...
|
|
|
Vasodialators 
